Mesoblast (NASDAQ:MESO) Downgraded by StockNews.com to “Sell”

StockNews.com lowered shares of Mesoblast (NASDAQ:MESO) from a hold rating to a sell rating in a research report sent to investors on Wednesday.

Separately, Cantor Fitzgerald reaffirmed an overweight rating on shares of Mesoblast in a report on Friday, January 12th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of Hold and an average price target of $13.67.

Mesoblast Stock Performance

NASDAQ MESO opened at $7.36 on Wednesday. Mesoblast has a one year low of $1.61 and a one year high of $10.24. The company has a 50-day simple moving average of $4.65 and a 200-day simple moving average of $3.02. The firm has a market capitalization of $840.35 million, a PE ratio of -6.78 and a beta of 3.45.

Institutional Investors Weigh In On Mesoblast

A number of hedge funds have recently made changes to their positions in MESO. Prosperity Wealth Management Inc. bought a new position in shares of Mesoblast in the third quarter worth $79,000. Chase Investment Counsel Corp bought a new position in Mesoblast in the 1st quarter valued at about $298,000. Finally, Lazari Capital Management Inc. grew its position in Mesoblast by 9.3% in the 3rd quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock valued at $116,000 after buying an additional 8,000 shares in the last quarter. Institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.